Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
CereMark Pharma General Information
CereMark Pharma is preparing for pivotal Phase 3 clinical trials of F-18 Flornaptitril, which has demonstrated in research the ability to simultaneously target and image both tau aggregates and beta-amyloid plaques associated with neurodegenerative diseases. Previous clinical studies have shown unique imaging capabilities on PET scans. The Phase 3 trial is planned to begin in late 2024.
Contact Information
Primary Industry
Biotech
Corporate Office
Wheeling, West Virginia
United States
United States
Drug Pipeline
F-18 Flornaptitril
Pre-clinicalKey Partnerships
Hall of Fame Health, Invicro, SpectronRx, UCLA
CereMark Pharma Funding
No funding data available
To view CereMark Pharma's complete valuation and funding history, request access »